A short social post suggesting the GLP-1 story goes beyond weight loss and the controversy around these drugs. It's light on specifics, so expect opinion rather than new data.
Recap by typeshit. Post by @getinthegroove1 on Instagram.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
Burley, who takes a GLP-1 himself, tells Forbes the drug ads say little about training and that gyms should be ready for people on them.
A retail broker ties GLP-1 drug habits, like drinking less and doing more Pilates, to shifts in which shops fill NYC retail space.
Loading…